Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Stayble Therapeutics: BioStock: Stayble's phase IIb study nears the finishing line

Stayble Therapeutics

Stayble Therapeutics' clinical phase IIb study with STA363 takes no break in the summer heat. Approximately 90 per cent of the patients have now completed their 12-month follow-up, which shows that the company has good opportunities to present top-line data during the fourth quarter of this year. The company's CEO Andreas Gerward tells us more in an interview.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/07/staybles-phase-iib-study-nears-the-finishing-line/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.